TrialCancer immunology, immunotherapy : CII2024

INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.

John F Hilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.